GLP1R Overview
Molecule Name
Glucagon-like peptide-1
Synonyms
GLP-1-R, GLP-1R, glucagon like peptide 1 receptor
Drug Development Progress
Drugs in Clinical Trials13
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
GLP-1
Background
G-protein coupled receptor for glucagon-like peptide 1 (GLP-1). Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels. Plays a role in regulating insulin secretion in response to GLP-1
GLP1R Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BioGlutide | NA-931 | Phase 3 Clinical | Biomed Industries Inc | Body Weight; Body Weight Changes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity; Overweight; Weight Loss | Details |
| Bionetide | NA-921 | Phase 3 Clinical | Biomed Industries Inc | Fragile X Syndrome; Rett Syndrome | Details |
| ZT-006 | ZT-006; ZT006 | Phase 2 Clinical | Beijing QL Biopharmaceutical Co Ltd | Alzheimer Disease; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| HM-15275 | HM15275; HM-15275 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Obesity | Details |
| SYH-2082 | SYH-2082; SYH2082 | Phase 1 Clinical | Beijing Kangchuanglian Biopharmaceutical Technology Research Co Ltd | Obesity; Overweight | Details |
| SNA-003 | SNA003; SNA-003 | Phase 1 Clinical | SN BioScience | Diabetes Mellitus; Obesity | Details |
| CA-111 | CA-111; CA111 | Phase 1 Clinical | Chongqing Chenan Biopharmaceutical Co Ltd | Body Weight | Details |
| ACT-300 | ACT300; ACT-300 | Phase 1 Clinical | Xiamen Amoytop Biotech Co Ltd | Digestive System Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| KAI-4729 | HRS-4729; KAI-4729 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| ZT-003 | ZT003; ZT-003 | Phase 1 Clinical | Beijing QL Biopharmaceutical Co Ltd | Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| ANY-002 | ANY-002; ANY002 | Phase 1 Clinical | Anya Biopharm Inc | Details | |
| KN-069 | KN069; KN-069 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Metabolic Diseases; Obesity; Overweight | Details |
| semaglutide (Lexaria Bioscience) | Clinical | Lexaria Bioscience Corp | Diabetes Mellitus | Details |